BiotechTube

Naloxegol + Naloxegol

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Induced Constipation

Conditions

Opioid Induced Constipation

Trial Timeline

Jul 1, 2012 → Sep 1, 2012

NCT ID
NCT01623609

About Naloxegol + Naloxegol

Naloxegol + Naloxegol is a phase 1 stage product being developed by AstraZeneca for Opioid Induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT01623609. Target conditions include Opioid Induced Constipation.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01623609Phase 1Completed

Competing Products

20 competing products in Opioid Induced Constipation

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
NKTR-118 + Usual careAstraZenecaPhase 3
77
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
85

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85